In vitro activity of cefepime and ceftazidime against 197 nosocomial blood stream isolates of streptococci: A multicenter sample

Diagnostic Microbiology and Infectious Disease

Volumn 29, Issue 4, 1997, Pages 273-276

  Pfaller, Michael A ^a   Marshall, Steven A ^a   Jones, Ronald N ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; ERYTHROMYCIN; PENICILLIN DERIVATIVE; VANCOMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ARTICLE; BACTEREMIA; BETA HEMOLYTIC STREPTOCOCCUS; DRUG ACTIVITY; DRUG POTENCY; HOSPITAL INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORINS; CROSS INFECTION; ERYTHROMYCIN; HUMANS; PENICILLINS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS; VANCOMYCIN;

EID: 0031406982     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(97)00139-9     Document Type: Article

References (20)

1. Alcaide F, Linares J, Pallanes R, Carratala J, Benitez MA, Gudiol F, Martin R (1995) In vitro studies of 22 β-lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group streptococci from blood. Antimicrob Agents Chemother 39:2243-3347.
2. Appelbaum PC (1992) Antibiotic resistance in Streptococcus pneumoniae: An overview. Clin Infect Dis 15:77-83.
3. Bochud PY, Eggeman P, Calandra T, Van Melle G, Saghofi L, Francioli P (1994a) Bacteremia due to viridans streptococcus in neutropenic patients with cancer: Clinical spectrum and risk factors. Clin Infect Dis 18:25-31.
4. Bochud PY, Calandra T, Francioli P (1994b) Bacteremia due to viridans streptococci in neutropenic patients: A review. Am J Med 97:256-264.
5. Breiman RF, Butler JC, Tenover FC, Elliot JA, Gacklam RR (1994) Emergence of drug-resistant pneumococcal infections in the United States. J Am Med Assoc 271:1831-1835.
6. Doern GV, Brueggeman A, Holley HP Jr, Rauch AM (1996a) Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: Results of a 30-center national surveillance study. Antimicrob Agents Chemother 40:1208-1213.
7. Doern GV, Ferraro MJ, Brueggeman AB, Ruoff KL (1996b) Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob Agents Chemother 40:891-894.
8. Ferrieri P, Kaplan EL (1992) Invasive group A streptococcal infections. Infect Dis Clin North Am 6:149-161.
9. Jernigan DB, Cetron MS, Breiman RF (1996) Minimizing the impact of drug-resistant Streptococcus pneumoniae (DRSP): A strategy from the DRSP working group. J Am Med Assoc 275:206-209.
10. Jones RN, Fuchs PC (1989) Activity of cefepime (BMY-28142) and cefpirome (HR 810) against Gram-negative bacilli resistant to cefotaxime or ceftazidime. J Antimicrob Chemother 23:163-165.
11. Jones RN, Kehrberg EN, Erwin ME, Anderson SC (1994) Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous centers in the United States. I. Study on the threat of emerging resistances: Real or perceived? Diagn Microbiol Infect Dis 19:203-215.
12. Klugman K, Goldstein F, Kohno S, Baquero F (1997) The role of fourth-generation cephalosporins in the treatment of infections caused by penicillin-resistant streptococci. Clin Microbiol Infect 3(suppl 1):S48-S60.
13. National Committee for Clinical Laboratory Standards (1997) Performance Standards for Antimicrobial Susceptibility Testing: 7th International Supplement, M100-S7. Wayne, PA: NCCLS.
14. Pfaller MA, Jones RN (1997) In vitro evaluation of contemporary β-lactam drugs tested against viridans group and β-haemolytic streptococci. Diagn Microbiol Infect Dis 27:151-154.
15. Renneberg J, Niemann LL, Gutschik E (1997) Antimicrobial susceptibility of 278 streptococcal blood isolates to seven antimicrobial agents. J Antimicrob Chemother 39: 135-140.
16. Saez-Llorens X, Castano E, Garcia E (1995) Prospective randomized comparison of cefepime and cefotaxime for treatment of bacterial meningitis in infants and children. Antimicrob Agents Chemother 39:937-940.
17. Sanders WE, Tenney JH, Kessler RE (1996) Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species. Clin Infect Dis 23:454-461.
18. Spangler SK, Jacobs MR, Appelbaum PC (1994) Susceptibilities of 177 penicillin-susceptible and -resistant pneumococci to FK-037, cefpirome, cefepime, ceftriaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem, and vancomycin. Antimicrob Agents Chemother 38:898-900.
19. Tauber MG, Hackbarth CJ, Scott KG, Rusnak MG, Sande MA (1985) New cephalosporins cefotaxime, cefpimizole, BMY 28142, and HR 810 in experimental pneumococcal meningitis in rabbits. Antimicrob Agents Chemother 27:340-342.
20. Thornsberry C, Yee YC (1996) Comparative activity of eight antibiotics against clinical bacterial isolates from the United States: Broth microdilution (MicroScan) and the Etest methods. Am J Med 100(suppl 6A):26S-38S.